FDA Approves Oral Daprodustat to Treat Anemia in Dialysis
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
Black patients without high-risk APOL1 alleles did not have higher risks for kidney failure.
Furthermore, use of anticoagulants induces higher incidence of GI bleeding in hemodialysis versus peritoneal dialysis patients
Iron deficiency associates with adverse outcomes in patients on peritoneal dialysis, regardless of anemia status.
Vaccination decreased the risk for COVID-related hospitalization and death, according to a retrospective study.
Higher financial incentives may be necessary to change clinician and facility behavior, investigators suggested.
In a study of 121 patients with lupus nephritis on dialysis, 26.4% experienced an SLE flare at a median of 17 months after dialysis initiation.
Both potassium binders effectively lowered serum potassium levels in patients on hemodialysis meeting hyperkalemia definitions, compared with no treatment, investigators reported.
Risk of fracture at specific sites differed by cause of kidney failure, investigators found.
5% decline seen in peritonitis rate per year; rate varied by patient factors, including age, race, prior peritoneal episodes